Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers

FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers

Oct 29, 2019
|
Turna Ray
Premium

NEW YORK – The latest approval of niraparib (GlaxoSmithKline's Zejula) for heavily pretreated ovarian cancer patients with homologous recombination deficiency (HRD) not only increases the number of patients eligible for the drug, but also adds another biomarker that oncologists can use to help them decide whether to prescribe this PARP inhibitor or another drug. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Letter Urges New Inquiry

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

Great Apes Get Shots, Too

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Woodcock on Vaccines, More

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

Science Paper Examines Molecular Contributors to Kidney Fibrosis

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Molecular Diagnostics

  1. Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

  2. Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

  3. FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

  4. Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

    Premium

  5. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.